NCT07162311

Brief Summary

Rheumatoid arthritis (RA) is a highly complex inflammatory autoimmune disease. Several drugs have been developed in recent decades to target the immune components of inflammation. However, even with effective anti-inflammatory and immunosuppressive therapies for controlling RA, many patients still report significant levels of chronic pain due to CNS neuroplasticity, perpetuating physical disability, psychosocial problems, decreased work activity, and poor quality of life. In addition, chronic pain can lead to increased public spending due to the need for more medical visits, ineffective drug treatments, and financial disability benefits. Transcranial stimulation (a noninvasive neural stimulation technique with minimal adverse effects and easy home use) has been a promising adjunct tool in the treatment of chronic pain and psychological disorders in diseases that affect the central nervous system in the long term. Thus, exploring transcranial direct current stimulation in RA patients with low levels of inflammation could impact on improving pain, functionality, psychological aspects and overall quality of life, as well as reducing healthcare costs for society.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at P25-P50 for not_applicable

Timeline
32mo left

Started Jan 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
Jan 2024Dec 2028

Study Start

First participant enrolled

January 1, 2024

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

April 7, 2025

Completed
5 months until next milestone

First Posted

Study publicly available on registry

September 9, 2025

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 22, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 22, 2028

Last Updated

September 9, 2025

Status Verified

April 1, 2025

Enrollment Period

5 years

First QC Date

April 7, 2025

Last Update Submit

September 4, 2025

Conditions

Keywords

Rheumatoid arthrtischronic paintDCS

Outcome Measures

Primary Outcomes (1)

  • VAS pain

    Visual Analogue Scale for pain

    Visual Analog Scale (VAS, 0-100 mm; higher scores indicate worse pain) assessed at baseline (Day 1), after 10 days of tDCS treatment, at Week 4 of tDCS treatment (end of treatment), and at 3, 6, 9, and 12 months post-treatment.

Study Arms (2)

Acitve tDCS

ACTIVE COMPARATOR

2 mA, 20 minutes/day, 5 days/week, for 4 weeks, applied at home under remote supervision.

Device: tDCS

Sham tDCS

SHAM COMPARATOR

Same parameters as active tDCS, but current was ramped down after 30 seconds to mimic sensation without delivering stimulation.

Device: tDCS

Interventions

tDCSDEVICE

Home-Based Transcranial Direct Current Stimulation

Acitve tDCSSham tDCS

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants aged 18-70 with RA.
  • Participants with generalized pain ≥ 40 mm on the VAS-Pain scale, lasting over 3 months, and not of mechanical or inflammatory origin, as assessed by a certified rheumatologist.
  • Evidence of low inflammatory markers, including with C-reactive protein (CRP) \<10 mg/dL and sedimentation rate (ESR) \<20 mm/h, and stable treatment for PsA for at least 6 months prior to study enrollment.

You may not qualify if:

  • History of brain surgery, traumatic brain injury, stroke, previous intracranial metal implantation, pregnancy, or breastfeeding.
  • Previous history of autoimmune diseases other than RA.
  • History of neurological diseases.
  • Previous history of neoplasia.
  • History of any other uncompensated clinical disease.
  • Use of illicit drugs within the past 6 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, 90880390, Brazil

Location

Related Publications (1)

  • Caumo W, Lopes Ramos R, Vicuna Serrano P, da Silveira Alves CF, Medeiros L, Ramalho L, Tomeddi R, Bruck S, Boher L, Sanches PRS, Silva DP Jr, Ls Torres I, Fregni F. Efficacy of Home-Based Transcranial Direct Current Stimulation Over the Primary Motor Cortex and Dorsolateral Prefrontal Cortex in the Disability Due to Pain in Fibromyalgia: A Factorial Sham-Randomized Clinical Study. J Pain. 2024 Feb;25(2):376-392. doi: 10.1016/j.jpain.2023.09.001. Epub 2023 Sep 7.

    PMID: 37689323BACKGROUND

MeSH Terms

Conditions

Rheumatic FeverChronic Pain

Interventions

Transcranial Direct Current Stimulation

Condition Hierarchy (Ancestors)

Streptococcal InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsConvulsive TherapyPsychiatric Somatic TherapiesBehavioral Disciplines and ActivitiesElectroshockPsychological Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator; PhD Student in Medical Sciences at the Federal University of Rio Grande do Sul

Study Record Dates

First Submitted

April 7, 2025

First Posted

September 9, 2025

Study Start

January 1, 2024

Primary Completion (Estimated)

December 22, 2028

Study Completion (Estimated)

December 22, 2028

Last Updated

September 9, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

The Individual Patient Data (IPD) will not be shared due to privacy and confidentiality concerns, as well as the protection of sensitive patient information. Additionally, there may be legal or regulatory restrictions that prevent the release of such data. Sharing of IPD could also raise ethical issues regarding informed consent and the use of data beyond the initial scope of the study.

Locations